Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:

Similar presentations


Presentation on theme: "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:"— Presentation transcript:

1 Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte by Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban, Karim Belhadj, Dominique Bordessoule, Christophe Fermé, and Hervé Tilly Blood Volume 116(12):2040-2045 September 23, 2010 ©2010 by American Society of Hematology

2 Progression-free survival in patients treated with CHOP and R-CHOP. Bertrand Coiffier et al. Blood 2010;116:2040-2045 ©2010 by American Society of Hematology

3 Overall survival in patients treated with CHOP and R-CHOP. Bertrand Coiffier et al. Blood 2010;116:2040-2045 ©2010 by American Society of Hematology

4 Disease-free survival in patients treated with CHOP and R-CHOP. Bertrand Coiffier et al. Blood 2010;116:2040-2045 ©2010 by American Society of Hematology

5 Survival after disease progression in patients initially treated with CHOP or R-CHOP. Bertrand Coiffier et al. Blood 2010;116:2040-2045 ©2010 by American Society of Hematology


Download ppt "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:"

Similar presentations


Ads by Google